Published in final edited form as:

J Neuroimmunol. 2019 June 15; 331: 46–57. doi:10.1016/j.jneuroim.2017.10.015.

The control of oligodendrocyte bioenergetics by interferon-gamma (IFN- γ) and Src homology region 2 domaincontaining phosphatase-1 (SHP-1)

Scott B. Minchenberg¹ and Paul T. Massa^{1,2,*}

¹Department of Microbiology and Immunology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, N.Y

²Department of Neurology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, New York

Abstract

Glycolysis and mitochondrial respiration are essential for oligodendrocyte metabolism in both the developing and adult CNS. Based on recent reports on the effects of the proinflammatory cytokine IFN- γ on metabolism and on oligodendrocytes, we addressed whether IFN- γ may affect oligodendrocyte bioenergetics in ways relevant to CNS disease. Oligodendrocytes of mice treated with IFN- γ showed significant reductions in aerobic glycolysis and mitochondrial respiration. As expected, IFN- γ treatment led to the induction of STAT1 in oligodendrocytes indicating active signaling into these cells. To determine the direct effects of IFN- γ on oligodendrocyte metabolism, cultured oligodendrocytes were treated with IFN- γ *in vitro*, which resulted in suppression of glycolysis similar to oligodendrocytes of animals treated with IFN- γ *in vivo*. Mice lacking SHP-1, a key regulator of IFN- γ and STAT1 signaling in CNS glia, had high constitutive levels of STAT1 and decreased aerobic glycolysis and mitochondrial respiration rates relative to wild type mouse oligodendrocytes. Together, these data show that IFN- γ and SHP-1 control oligodendrocyte bioenergetics in ways that may relate to the role of this cytokine in CNS disease.

Graphical abstract

*Corresponding author: Correspondence to Paul T. Massa, MassaP@upstate.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords

Cytokine signaling; Interferon gamma [IFN- γ]; SHP-1 [PTPN6]; Glycolysis; Mitochondria; Metabolism

1.1 Introduction

Oligodendrocyte bioenergetics is an area of active research, in which abnormalities in glycolysis or oxidative phosphorylation (OXPHOS) have been implicated in various processes associated with oligodendrocyte and neuronal dysfunction (Amaral et al., 2013, Funfschilling et al., 2012, Saab et al., 2013). The latter studies demonstrated that glial cells are highly glycolytic even under normoxic conditions. In particular, oligodendrocytes, which make extensive contact with axons to provide electrical insulation necessary for saltatory conduction, have been shown to provide lactate from glycolysis as metabolic fuel for axonal mitochondria (Lee et al., 2012, Rinholm et al., 2011).

In addition to maintaining the high-energy demands of axons, glycolysis and OXPHOS are required to meet the unique metabolic demands of oligodendrocytes. When actively myelinating, oligodendrocytes have a high bioenergetic demand and require both mitochondrial and glycolytic metabolism to allow for the synthesis of the myelin sheathes (Funfschilling et al., 2012, Ziabreva et al., 2010). Adequate mitochondrial function is particularly important during myelination, and diminished oligodendrocyte mitochondrial function is associated with hypomyelination and axonal degeneration (Andrews et al., 2005, Bjartmar and Trapp, 2001, Mahad et al., 2009, Takikita et al., 2015). After myelination is complete, oligodendrocytes can maintain myelin by utilizing glycolysis independently from mitochondrial respiration (Funfschilling et al., 2012). Recently, it has been reported that downregulation of glycolysis in cultured primary oligodendrocytes triggers process withdrawal, a mechanism oligodendrocytes might utilize to conserve energy in an effort to prevent apoptosis due to bioenergetics failure in vivo (Rone et al., 2016). Thus, both glycolytic and mitochondrial metabolism are essential in the context of myelination and axonal bioenergetics, and the pathways regulating these processes are critical for oligodendrocyte function and survival.

In the human demyelinating disease, multiple sclerosis (MS), oligodendrocytes may be direct targets for immune-mediated damage leading to subsequent demyelination. In this regard, extensive research has been conducted on the effects IFN- γ on oligodendrocyte biology and demyelination. IFN- γ is a proinflammatory cytokine that is relevant in the context of inflammatory demyelination since IFN- γ is produced by and mediates demyelinating activity by encephalitogenic T-cells in autoimmune models of MS (Balabanov et al., 2007, Goverman, 2009, Lees and Cross, 2007, Lin et al., 2007, Loda and Balabanov, 2012, Renno et al., 1998) and is produced by anti-viral T cells important for antiviral activities and cell death of oligodendrocytes in viral models of demyelination (Bergmann et al., 2003, De-Simone et al., 2015, Gonzalez et al., 2005, Parra et al., 2010, Schijns et al., 1991, Tsunoda et al., 2006). An important aspect of these studies on IFN- γ using these models is that both detrimental and beneficial outcomes have been reported which is not currently understood (Lin et al., 2006, Sosa et al., 2015, Vartanian et al., 1995, Willenborg et al., 1996). In this regard, IFN- γ acts on oligodendrocytes to induce STAT1 homodimers, a major component of proinflammatory, antiviral, and bioenergetic signaling (Agresti et al., 1998, Boehm et al., 1997, Decker et al., 1997). We propose that as found in other cells, that STAT1 acts to modulate bioenergetics in oligodendrocytes and is critical to the activity of IFN- γ on oligodendrocytes.

There are multiple regulators of IFN- γ signaling that are likely to have profound effects on responsiveness in oligodendrocytes. One in particular is the protein tyrosine phosphatase SHP-1, which has been shown to negatively regulate IFN- γ activity in multiple tissues and cell types (Shuai and Liu, 2003, Starr and Hilton, 1999, Valentino and Pierre, 2006). SHP-1 is a major regulator of IFN- γ signaling in CNS glia (Massa et al., 2000, Massa and Wu, 1996), however whether SHP-1 controls IFN- γ responsiveness in oligodendrocytes is unknown. Of particular interest in this regard, SHP-1-deficient (motheaten, me/me) mice display a significant degree of oligodendrocyte pathology (Wishcamper et al., 2001), dysmyelination (Massa et al., 2004) and astrogliosis (Horvat et al., 2001), consistent with a role for SHP-1, IFN- γ , and STAT1 activity in oligodendrocyte biology (Gruber et al., 2015, Massa et al., 2000). The main question in the present studies is whether these responses to IFN- γ may be coincident with alteration in oligodendrocyte bioenergetics. Our findings suggest that IFN- γ STAT1, and SHP-1 signaling in oligodendrocytes induces metabolic alterations in oligodendrocytes that are related to mechanisms of oligodendrocyte pathology and demyelinating disease.

1.2 Materials & Methods

Animals

SHP-1-deficient mice (motheaten locus, me/me) on a C3HeB/FeJLe-a/a background (RRID:IMSR_JAX:000225) and phenotypically normal littermates (wild type, WT) were produced from heterozygous breeding pairs obtained from Jackson Laboratories (Bar Harbor, ME). The strain designation for heterozygous breeders for motheaten mice is C3FeLe.B6 a/a-Ptpn6me/J (stock no. 000225). Both male and female mice were used throughout studies described below. All animal procedures were approved by the Institutional Animal Care and Use Committee at SUNY Upstate Medical University in

compliance with the National Institutes of Health Guide for Care and Use of Laboratory Animals.

Isolation of Oligodendrocytes from the Mouse CNS

Wild type and motheaten mice that were 7- or 8-days old were perfused with 20 mL of phosphate buffered saline (PBS) or PBS with 100 μ M sodium pervanadate, pH 7.4. Brains and spinal cords of 7- or 8-day-old wild type and motheaten mice were dissociated using a neural tissue dissociation kit (Miltenyi Biotec, San Diego, CA) according to the manufacturer's instructions, and oligodendrocytes were purified using O4 antibody conjugated to magnetic beads. The O4-positive oligodendrocytes were passed through a magnetic column on a QuadroMACS™ Separator (Miltenyi Biotec, San Diego, CA) to remove unlabeled glia and neurons. Although the resulting O4-isolated population displayed characteristic morphological criteria of oligodendrocytes by phase contrast microscopy (rounded cell bodies with multiple fine caliber processes) (Massa et al., 2000), immunofluorescence staining of this preparation for the oligodendrocyte marker myelin basic protein (MBP) showed that only about half the cells were positive (supplemental data, figure 1). We concluded based on these observations that O4-positive cells isolated from P7 animals represent a heterogeneous mixture of both mature MBP+ oligodendrocytes and less mature MBP-negative cells that may be oligodendrocyte progenitor cells (OPC). However, we refer to these preparations simply as oligodendrocytes.

Western Immunoblots

Whole-cell extracts were prepared as previously described (Massa et al., 2004). Cells or tissues were homogenized in RIPA buffer. 50 to 100 micrograms of protein per lane was electrophoresed through a 10% or 12% polyacrylamide resolving gel and electroblotted to a polyvinylidene difluoride membrane (Millipore, Billerica, MA). Membranes were blocked with 5% bovine serum albumin for 1 h, and then incubated with one of the following primary antibodies: Y701-pSTAT1 (Cell Signaling Technology Cat# 9167S RRID:AB_561284), total STAT1 (Cell Signaling Technology Cat# 9172 RRID:AB_2198300), Y705-pSTAT3 (Cell Signaling Technology Cat# 9145 also 9145S, 9145P, 9145L RRID:AB_2491009), total STAT3 (Cell Signaling Technology Cat# 12640 also 12640S RRID:AB_2629499), GAPDH (Cell Signaling Technology Cat# 5174 also 5174P, 5174S RRID:AB_10622025), or actin (Abcam Cat# ab3280 RRID:AB_303668), followed by HRP-conjugated IgG secondary antibody (DAKO Corporation, Carpinteria, CA). Enhanced chemiluminescence (Amersham Life Sciences, Cleveland, OH) was used to visualize reactive protein bands on the ChemiDOC, and quantified using the Image Lab software (Bio-Rad, Hercules, CA).

In Vivo Treatment of Mice with Cytokines

P6–8 wild type and motheaten mice were injected I.P. with 100 μ L of IFN- γ (R&D Systems, Minneapolis, MN) in PBS with 0.5% BSA at a concentration of 100U/g body weight. PBS with 0.5% BSA was used as a vehicle control and injected at a volume of 100 μ L. After 24 hours of cytokine treatment, the brains and spinal cords were removed and the O4⁺ oligodendrocytes were isolated and analyzed as outlined above.

***In vivo* Metabolic Analysis**

Oligodendrocytes freshly isolated from wild type and motheaten mouse brains and spinal cords were plated on Seahorse XF^e96 cell culture microplates (Agilent, Santa Clara, CA) that were pretreated for 20 minutes with Cell-Tak (Corning Inc, Corning, NY) at a concentration of 3.5 µg Cell-Tak/cm² of surface area. The oligodendrocytes were plated at a density of 200,000 live cells per well and incubated in 175 µL of XF Base media (Agilent, Santa Clara, CA) with 2mM glutamate at a pH of 7.4 for analysis of glycolysis or in 175 µL of XF base media (Agilent, Santa Clara, CA) with 25mM glucose, 2mM glutamate, and 1mM pyruvate at a pH of 7.4 for analysis of mitochondrial function. The cells were incubated at 37 C° for one hour and were analyzed using the Seahorse XF^e96 Analyzer. Four cycles were performed which consisted of 3 minutes of mixing followed by three minutes of measuring. For measuring glycolysis, the basal extracellular acidification rate (ECAR) was measured in the first cycle. After the first cycle was completed, 25 µL of glucose was injected so that the working concentration was 10mM and the second cycle measured the changes in ECAR after the introduction of glucose. After the second cycle was completed, 25 µL of the ATPase inhibitor oligomycin was injected (final concentration, 2 µM). Finally, 2-deoxy-D-glucose (2-DG) was injected to a final concentration of 50 mM. The rate of basal glycolysis was determined by subtracting the ECAR before the glucose injection from the ECAR after the glucose injection. The glycolytic capacity was determined by subtracting the ECAR after glucose injection from the ECAR after the oligomycin injection. *A schematic diagram illustrating this analysis is shown in supplementary figure 2.*

For quantifying alterations in mitochondrial metabolism, the basal oxygen consumption rate (OCR) was measured followed by a 25 µL injection of oligomycin to give a final oligomycin concentration of 2µM, a second 25 µL injection of carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) (final concentration of 2 µM), and a third 25 µL injection of rotenone/antimycin A to give a final concentration of 0.5 µM. The basal mitochondrial oxygen consumption was calculated by subtracting the OCR independent of mitochondrial function (OCR measured after rotenone/antimycin A injection) from the basal OCR of the cell. The maximal mitochondrial respiration was measured by subtracting the OCR obtained after rotenone/antimycin A injection from the OCR after FCCP treatment. The mitochondrial ATP production was calculated by subtracting the basal oxygen consumption from the oxygen consumption after oligomycin treatment. Finally, the spare respiratory capacity was calculated by subtracting the OCR after FCCP treatment from the basal cellular OCR. *A schematic diagram illustrating this analysis is shown in supplementary figure 2.* The metabolic data for the oligodendrocytes were analyzed using the Wave software (Agilent, Santa Clara, CA). The cell loading was standardized to GAPDH levels in oligodendrocytes isolated from each group since IFN-γ treatment and genotype did not have any significant effect on oligodendrocyte GAPDH levels.

***In vitro* Cytokine Treatments and Oligodendrocyte Cultures**

Oligodendrocytes from P6–P8 mice were isolated from wild type as outlined above. The oligodendrocytes were plated on Seahorse XF^e96 cell culture microplates (Agilent, Santa Clara, CA) that were pretreated for 20 minutes with Cell-Tak (Corning Inc, Corning, NY) at a concentration of 3.5 µg Cell-Tak/cm² of surface area. The oligodendrocytes were cultured

for 24 hours in complete culture medium containing Dulbecco's modified Eagle's medium (DMEM, Gibco, Carlsbad, CA), 10% FBS (Gibco, Carlsbad, CA), 100 U/mL of penicillin, 100 µg/mL of streptomycin, and 0.5 % BSA in PBS, 100 U/mL of IFN- γ (R&D Systems, Minneapolis, MN), or 100 U/mL of LIF R&D Systems, Minneapolis, MN).

***In vitro* Metabolic Analysis**

After 24 hours in culture, the culture media was washed and replaced with 175 µL of XF Base media (Agilent, Santa Clara, CA) with 10mM glucose and 2mM glutamate at a pH of 7.4 for analysis of glycolysis or in 175 µL of XF base media (Agilent, Santa Clara, CA) with 25mM glucose, 2mM glutamate, and 1mM pyruvate at a pH of 7.4 for analysis of mitochondrial function. The cells were incubated at 37 C° for one hour and were analyzed using the Seahorse XF^e96 Analyzer as described above.

The rate of basal glycolysis was determined by subtracting the average ECAR after 2-DG injection from the average ECAR after the glucose injection. The glycolytic capacity was determined by subtracting the average ECAR after glucose injection from the average ECAR after the oligomycin injection.

The basal mitochondrial oxygen consumption was calculated by subtracting the average OCR independent of mitochondrial function (OCR measured after rotenone/antimycin A injection) from the average basal OCR of the oligodendrocytes. The maximal mitochondrial respiration was measured by subtracting the average OCR obtained after rotenone/antimycin A injection from the average OCR after FCCP treatment. The mitochondrial ATP production was calculated by subtracting the average basal oxygen consumption from the average oxygen consumption after oligomycin treatment. Finally, the spare respiratory capacity was calculated by subtracting the average OCR after FCCP treatment from the average basal cellular OCR. The metabolic data for the oligodendrocytes were analyzed using the Wave software (Agilent, Santa Clara, CA). The cell loading was standardized using CyQUANT to account for alterations in cell viability.

Statistical Analysis

Histograms and tables show the mean values with standard error of the mean. The numbers of samples or individual mice used in each assay are indicated in the figure legends. For comparisons between two samples, p-values were generated using the unpaired Student's t test. For comparisons between more than two samples, statistical significance was determined by an ANOVA. The particular test used for each experiment is indicated in the figure legends. A p-value of less than 0.05 was interpreted as statistically significant. All statistical analyses were performed using Graphpad Prism (version 7).

1.3 Theory

The cytokine IFN- γ has been shown to have multiple important biological activities in oligodendrocytes ranging from increased expression of immune molecules, cell death induction, and anti-viral state. Recently, the role of specific bioenergetic pathways in these IFN- γ responses has been discovered. Therefore, the role of IFN- γ in altering the

bioenergetic state of oligodendrocytes may provide important mechanistic insights into how IFN- γ acts on oligodendrocytes in health and disease.

1.4 Results

Treatment of Mice with IFN- γ Suppresses Oligodendrocyte Glycolytic and Mitochondrial Metabolism

Previous studies have demonstrated that IFN- γ regulates bioenergetics in many cell types (Karhumaki and Helin, 1987, Su et al., 2015) and IFN- γ signaling is relevant to mechanisms of oligodendrocyte pathology and inflammatory demyelination in MS. Of particular relevance to oligodendrocyte viability and myelination is glycolytic and mitochondrial respiration (Rone et al., 2016). To determine the effects of IFN- γ on wild type mouse oligodendrocyte bioenergetics *in vivo*, we treated wild type mice with IFN- γ for 24 hours and conducted metabolic studies on freshly isolated oligodendrocytes from brain and spinal cord. Oligodendrocytes of mice treated with IFN- γ for 24 hours displayed both decreased basal aerobic glycolysis and glycolytic capacity (Fig. 1A–C; Supplementary figure 2). Moreover, oligodendrocytes from IFN- γ -treated wild type mice had significantly reduced parameters of mitochondrial metabolism including basal mitochondrial oxygen consumption, maximal mitochondrial respiration, ATP production, and spare respiratory capacity relative to untreated wild type mice (Fig. 1D–H, Supplementary figure 2). Trypan blue staining revealed no alterations in oligodendrocyte viability after *in vivo* IFN- γ treatment relative to oligodendrocytes isolated from untreated animals (data not shown). Overall, we demonstrated that IFN- γ significantly reduced oligodendrocyte glycolytic and mitochondrial metabolism.

Direct effects of IFN- γ on oligodendrocyte metabolism

Based on the effects of IFN- γ on oligodendrocyte bioenergetics *in vivo*, we wanted to determine if IFN- γ could act directly on oligodendrocyte bioenergetics. To determine the direct effects of IFN- γ on oligodendrocyte metabolism, freshly isolated oligodendrocytes from brain and spinal cord were cultured for 24hr in the presence of IFN- γ prior to metabolic analysis. IFN- γ significantly reduced basal glycolysis and glycolytic capacity (Fig. 2A–C), a finding that agreed with effects of *in vivo* IFN- γ treatment (Fig. 1A–C). However, in contrast to *in vivo* treatment, *in vitro* treatment with IFN- γ significantly increased basal mitochondrial oxygen consumption (Fig. 2D,E) but had no effect on maximal mitochondrial respiration, mitochondrial ATP production, or spare respiratory capacity (Fig. 2D,F–H). This suggests that IFN- γ directly impacts oligodendrocyte glycolysis, whereas the effects on mitochondrial function on oligodendrocyte mitochondria may be indirect, potentially involving other factor (s)/cell type (s) present *in vivo*.

Activation of STAT1 in oligodendrocytes by IFN- γ

To determine whether IFN- γ treatment was signaling in oligodendrocytes, *in vivo*- and *in vitro*-treated oligodendrocytes were analyzed by western immunoblot for STAT1, as IFN- γ is a major stimulus of STAT1 phosphorylation, activation, and positive STAT1 gene autoregulation (Boehm et al., 1997, Decker et al., 1997). Thus, IFN- γ treatment of mice and oligodendrocyte cultures led to a significant induction of STAT1 tyrosine phosphorylation

(Fig. 3A,C) that is known to be critical for activation of STAT1 transcriptional activity. The latter was consistent with the induction of total STAT1 protein in oligodendrocytes by IFN- γ treatment by autoregulation (Fig. 3A,C). Since STAT3 activation is known to elicit metabolic changes (Meier and Lerner, 2014, Poli and Camporeale, 2015, Sarafian et al., 2010, Wegrzyn et al., 2009), the levels of Y705-pSTAT3 were quantified as a control for possible cross talk between signal transduction pathways. IFN- γ treatment in mice and in oligodendrocyte cultures elicited no significant changes in the induction of Y705-pSTAT3 or total STAT3 in oligodendrocytes (Fig. 3B,D). Taken together, these data show that both *in vivo* and *in vitro* IFN- γ treatment activated STAT1 but had no effects on STAT3 activation in oligodendrocytes.

Regulation of STAT1 by SHP-1 in oligodendrocytes

Since IFN- γ activates STAT1 which may relate to changes in bioenergetics, we quantified the constitutive and IFN- γ -inducible activation of STAT1 in wild type and SHP-1-deficient (motheaten, *me/me*) oligodendrocytes. Regulation of STAT1 activity by SHP-1 in oligodendrocytes would be consistent with the regulation of STAT1 activity described in primary cultured astrocytes in response to IFN- γ stimulation (Massa and Wu, 1996). An additional rationale for this analysis was based on previous reports of SHP-1 expression in oligodendrocytes and oligodendrocyte pathology in *me/me* mice that might be related to expected bioenergetic suppression (Massa et al., 2000, Massa et al., 2004). As a measure of relative STAT1 activity between genotypes, we analyzed the expression of total STAT1, as STAT1 levels reflect STAT1-mediated transcriptional autoregulation (Boehm et al., 1997, Decker et al., 1997, Wong et al., 2002). Oligodendrocytes isolated from SHP-1-deficient mice constitutively expressed significantly more total STAT1 relative to oligodendrocytes of wild type mice indicating a significantly higher level of STAT1 activity (Fig. 4A). To the contrary, oligodendrocytes from SHP-1-deficient mice expressed similar amounts of Y705-pSTAT3 and total STAT3 compared to wild type mice (Fig. 4B). To demonstrate a role for SHP-1 as a negative regulator of IFN- γ signaling in oligodendrocytes, we quantified the induction of Y701-pSTAT1 and total STAT1 after *in vitro* IFN- γ treatment of wild type and SHP-1-deficient oligodendrocytes. After 24 hours of IFN- γ stimulation, both wild type and motheaten mouse oligodendrocytes had a significant induction of both Y701-pSTAT1 and total STAT1 (Fig. 4C–E), however IFN- γ induced significantly more Y701-pSTAT1 and total STAT1 in SHP-1-deficient oligodendrocytes (Fig. 4C–E) demonstrating a direct role for SHP-1 in the regulation of the STAT1 response to IFN- γ . To show specificity of IFN- γ -mediated activation of STAT1 in oligodendrocytes (i.e. crosstalk between signaling pathways) we treated wild type and SHP-1-deficient oligodendrocytes *in vitro* with leukemia inhibitory factor (LIF) which resulted in no observable induction of STAT1 in either wild type or motheaten oligodendrocytes (Fig. 4E). In sum, our data indicate a critical role for SHP-1 in controlling STAT1 activation in oligodendrocytes.

SHP-1 controls constitutive glycolytic and mitochondrial metabolism

After observing that IFN- γ downregulated metabolism in oligodendrocytes of wild type mice, we wanted to determine if oligodendrocytes of SHP-1-deficient mice displayed constitutively depressed bioenergetics compared to wild type oligodendrocytes. We believed that this was a distinct possibility as these SHP-1-deficient cells exhibited an abnormally

heightened STAT1 activation independently of IFN- γ (Figure 4A) as previously seen in SHP-1-deficient macrophages (David et al., 1995). As expected, oligodendrocytes isolated from SHP-1-deficient mice had a significant reduction in both basal glycolysis and glycolytic capacity relative to wild type oligodendrocytes (Fig. 5A–C). As well, we observed a significant decrease in basal mitochondrial oxygen consumption, maximal mitochondrial respiration, ATP production, and spare respiratory capacity (Fig. 5D–H) consistent with data obtained from oligodendrocytes of IFN- γ -treated wild type mice (Fig. 1A–H). It is important to note that there were no differences in viability between wild type and SHP-1-deficient mouse oligodendrocytes as determined by trypan blue staining (data not shown). Taken together, these data showed that loss of SHP-1 expression in oligodendrocytes led to a loss in both glycolytic and mitochondrial metabolism in oligodendrocytes. Therefore, SHP-1 expression in oligodendrocytes is critical for maintaining normal bioenergetics in oligodendrocytes. Because we determined that SHP-1 controls STAT1 signaling in oligodendrocytes, and increased STAT1 correlated with deficient glycolytic and mitochondrial metabolism, we attempted to enhance the metabolic defects in SHP-1-deficient oligodendrocytes by treating SHP-1-deficient mice with IFN- γ for 24 hours. After 24 hour IFN- γ treatment, there was a significant *yet subtle* induction in total STAT1 in the oligodendrocytes isolated from these mice (Fig 6A) but no effects on the induction of Y705-pSTAT3 (Fig. 6B). However, unlike the effects of *in vivo* IFN- γ treatment of wild type mice on downregulating oligodendrocyte metabolism (Fig. 1A–H), there were no effects of *in vivo* IFN- γ treatment on SHP-1-deficient oligodendrocytes for all parameters of glycolytic and mitochondrial metabolism (Fig. 7A–H). Based on this outcome, it was concluded that constitutive STAT1 activation in the absence of SHP-1 led to maximal suppression of oligodendrocyte bioenergetics that *could* not be further suppressed with IFN- γ . The latter supported the hypothesis that SHP-1-deficient cells displayed a constitutive STAT1 activation independent of IFN- γ exposure (Figure 4A) consistent with constitutively suppressed bioenergetic activities (Figure 5).

1.5 Discussion

To our knowledge, we are the first to describe a role for IFN- γ and SHP-1 in the regulation of glycolytic and mitochondrial metabolism in oligodendrocytes as schematically represented in figure 8. IFN- γ is known to induce STAT1 transcriptional activity, and relates to previous studies showing that STAT1 impacts aerobic glycolytic and mitochondrial metabolism in a cell type-specific manner that may be either inhibitory or stimulatory (Avalle et al., 2012, Meier and Lerner, 2014, Pitroda et al., 2009, Szczepanek et al., 2012, Wong et al., 2002). Here we show that *in vivo* delivery of exogenous IFN- γ impacts oligodendrocytes via downregulation of various parameters of both glycolytic and mitochondrial metabolism. We further corroborate this observation in oligodendrocytes of SHP-1-deficient mice which exhibit a constitutive “IFN- γ like state” with increased STAT1 activity and altered bioenergetics independent from exposure to IFN- γ .

In this manuscript, we show a role for IFN- γ in the regulation of metabolism that may provide insight into a potential novel mechanism for the impact of IFN- γ on oligodendrocytes. Besides mature oligodendrocytes, we have considered the possibility that a large proportion of O4-isolated cells from P7 animals may be oligodendrocyte progenitor

cells (OPC) and that OPC might contribute in a unique way to the observed bioenergetics profiles in our preparations. As such, bioenergetics measurements of these preparations may be an average between either distinct or similar responses to the treatments. Future experiments will be aimed at separating these populations to characterize their degree of maturational differences with respect to both aerobic glycolysis and mitochondrial respiration. Such differences might reflect on how IFN- γ may affect either maturation of OPC or mature oligodendrocyte functions.

As an approach to demonstrate the effect of IFN- γ on glycolysis and mitochondrial respiration, wild type mice were treated *in vivo* with IFN- γ . IFN- γ specifically induced significant STAT1 activation in wild type mouse oligodendrocytes (Fig. 3A) that was associated with a significant decrease in all measures of oligodendrocyte bioenergetics (Fig. 1A–H). In particular, oligodendrocytes isolated from IFN- γ -treated mice had significantly reduced basal glycolysis (Fig. 1B). Reduced oligodendrocyte basal glycolysis is thought to promote cell survival at the cost of myelination as recently described by Antel and coworkers (Rone et al 2016). Therefore, in the context of neuroinflammation, IFN- γ may be acting via bioenergetic alterations to preserve oligodendrocyte survival while inhibiting myelination until the inflammation has resolved. Glycolytic capacity was also significantly reduced in oligodendrocytes after IFN- γ treatment (Fig. 1C) suggesting that IFN- γ may be transcriptionally downregulating glycolytic enzymes. Typically, when glycolysis is inhibited, mitochondrial metabolism will compensate for the reduction in glycolytic metabolism (reverse Warburg effect), however *in vivo* treatment of wild type mice with IFN- γ also elicited a downregulation of all parameters of mitochondrial metabolism (Fig. 1D–H). The IFN- γ -induced reduction of basal mitochondrial oxygen consumption, maximal mitochondrial respiration, mitochondrial ATP production, and spare mitochondrial respiratory capacity (Fig. 1D–H) suggest pathways by which oligodendrocytes may cope with stressful situations related to inflammation and/or remyelination. As the reduction of mitochondrial metabolism in the context of reduced glycolysis was an unexpected result and we did not see this reduction in isolated oligodendrocytes *in vitro*, we presumed that the *in vivo* effects of IFN- γ on mitochondrial function in oligodendrocytes could be indirect via the effect of IFN- γ on other CNS cells (Cannella and Raine, 2004). We hypothesize that the reduction of mitochondrial metabolism can be attributed to inducible nitric oxide synthase (iNOS) induced by IFN- γ in astrocytes and microglia (Tran et al., 2000) which would increase nitric oxide (NO) levels in the CNS leading to nitrosylation and inhibition of the electron transport chain (ETC) (Heales et al., 1999) (Figure 8). Since oligodendrocytes provide a major energy source to axons in the form of lactate transferred via MCT channels (Funfschilling et al., 2012), IFN- γ downregulation of oligodendrocyte mitochondrial metabolism in the context of reduced glycolysis may be a counteractive mechanism to augment lactate levels for use in axonal metabolism under stressful conditions. Our *in vivo* findings likely represent complex interactions between multiple IFN- γ -responsive cells in which the end result on suppressed oligodendrocyte bioenergetics may not strictly extend to whether IFN- γ is either beneficial or detrimental to oligodendrocytes *in vivo* but likely involves other factors including iNOS induced by IFN- γ in the CNS (Tran et al., 2000) (Figure 8). Additionally, the role of IFN- γ on induction of antiviral state in oligodendrocytes has been demonstrated which may be beneficial or detrimental in controlling virus-induced

demyelinating disease caused by oligodendrocyte-tropic viruses (Bergmann et al., 2003, De-Simone et al., 2015, Gonzalez et al., 2005, Parra et al., 2010, Schijns et al., 1991, Tsunoda et al., 2006). Of particular interest, the present studies may relate to a novel mechanism of antiviral state induced by IFN- γ in oligodendrocytes as numerous viruses rely on aerobic glycolysis for efficient replication (Allonso et al., 2015, Findlay and Ulaeto, 2015, Fontaine et al., 2015, Liu et al., 2015, Ma et al., 2015, Sanchez and Lagunoff, 2015).

Based on previous studies in our laboratory on the role of SHP-1 on oligodendrocyte biology, we favor the possibility that increased IFN- γ , STAT1, and reduced bioenergetics especially in the context of SHP-1-deficiency may be directly detrimental to oligodendrocytes by various mechanisms including apoptosis. For instance, the induction of the STAT1 responsive genes by IFN- γ has also been shown to promote apoptosis in both mature oligodendrocytes (Agresti et al., 1998, Balabanov et al., 2006, Buntinx et al., 2004) and oligodendrocyte progenitor cells (OPC) (Tirota et al., 2011). We envision that severe bioenergetics suppression may augment cytotoxic effects of IFN- γ in oligodendrocytes. Having stated this, the effect of IFN- γ on oligodendrocytes is complex with regard to apoptosis and cell survival as IFN- γ has been shown to protect against oligodendrocyte apoptosis and demyelination in experimental autoimmune encephalitis in mice (Balabanov et al., 2007) indicating that some degree of bioenergetics suppression may be protective against oligodendrocyte toxicity and dysfunction as proposed recently (Rone et al., 2016). As a possible mechanism of IFN- γ -induced apoptosis related to the present studies, the reduced activity of aerobic glycolysis by IFN- γ would affect both ATP production and flux through the associated pentose phosphate pathway (PPP) leading to a depletion of reduced glutathione (GSH) and consequent oxidative damage to oligodendrocyte mitochondria. Such damage and ATP depletion has been shown to cause cytochrome C leakage into the cytoplasm and induction of the intrinsic apoptotic pathway (Garcia-Perez et al., 2012, Garedeu et al., 2010, Watanabe et al., 2003).

To verify that IFN- γ signaled into oligodendrocytes, STAT1 phosphorylation and expression were measured. STAT1 transcriptionally autoregulates its own expression (Wong et al., 2002) and thus increased total STAT1 in IFN- γ treated wild type oligodendrocytes coincides with increased Y701-pSTAT1 (Fig. 3A,C). Throughout this study, activated STAT3 (Y705-pSTAT3) was used as a control since “cross-talk” between IFN- γ -induced STAT1 signaling may occur via SOCS3 mediated downregulation of Y705-STAT3. Thus, it was important to show specificity for IFN- γ signaling in oligodendrocytes, especially in the context of SHP-1 deficiency. We observed a strong correlation between the induction of STAT1 and metabolic alterations in oligodendrocytes. Therefore, it is feasible that IFN- γ may be exerting its effects on oligodendrocyte metabolism through STAT1 transcriptional activity. Metabolic regulation by STAT1 has been previously described in other cell types and it is possible that this may be the mechanism behind IFN- γ induced metabolic alterations of oligodendrocytes (David et al., 1995, Hiroi et al., 2009, Pitroda et al., 2009, Ramana et al., 2000, Sisler et al., 2015).

Oligodendrocytes from SHP-1-deficient (motheaten, me/me) mice were analyzed since SHP-1 is a major negative regulator of IFN- γ signaling in CNS glia (Massa and Wu, 1996). Oligodendrocytes isolated from SHP-1-deficient mice had significantly higher constitutive

STAT1 activation (Fig. 4A), but no significant differences in STAT3 activation compared to those of wild type mice (Fig. 4B). Previous research has determined that SHP-1-deficient cells have deranged IFN signaling and therefore respond to IFN- α and IFN- β the same way they respond to IFN- γ with increased STAT1 homodimer activation (David et al., 1995). This makes it highly likely that the constitutively elevated STAT1 in SHP-1-deficient oligodendrocytes represents STAT1 in an “IFN- γ like state”. Further, the induction of Y701-pSTAT1 and total STAT1 after IFN- γ treatment were significantly higher in SHP-1-deficient oligodendrocytes relative to IFN- γ -treated wild type oligodendrocytes (Fig. 4C–E), thus demonstrating a direct role for SHP-1 in controlling IFN- γ signaling in oligodendrocytes. High STAT1 correlated with reduced parameters of glycolytic and mitochondrial metabolism in SHP-1-deficient oligodendrocytes (Fig. 5A–H) and recapitulated the metabolic alterations described in wild type oligodendrocytes treated with IFN- γ (Fig. 1A–H). Surprisingly, IFN- γ did not have any effects on glycolytic or mitochondrial metabolism in oligodendrocytes isolated from SHP-1-deficient mice (Fig. 7A–H) even though IFN- γ significantly increased total STAT1 expression (Fig. 6A). We attribute this unexpected result to the constitutive “IFN- γ like state” already established by the significantly higher STAT1 levels in SHP-1-deficient oligodendrocytes (Fig. 4A). Therefore, SHP-1-deficient oligodendrocytes may be maximally metabolically repressed rendering the excess total STAT1 induced by IFN- γ ineffective in further reducing metabolism.

Defects in glycolytic and mitochondrial metabolism can cause deficits in myelination since lipid synthesis is highly dependent upon metabolites generated by both glycolysis and the mitochondria. We have previously demonstrated that white matter tracts in the CNS of SHP-1-deficient mice display dysmyelination and oligodendrocyte abnormalities (Massa et al., 2000, Massa et al., 2004). We propose that defects in SHP-1-deficient oligodendrocyte glycolytic and mitochondrial metabolism are major factors driving dysmyelination in these mice. In support, oligodendrocytes are dependent on adequate metabolic function to properly myelinate axons and maintain myelin sheaths after myelination has occurred (Funfschilling et al., 2012). To explain this dependence, mitochondrial respiration, glycolysis and the associated PPP are critical in providing both large amounts of ATP and metabolites for the proliferation of oligodendrocyte progenitors and the synthesis of myelin lipids and proteins during active myelination (Steiner et al., 2014, Sykes et al., 1986). Recent work has addressed possible relevance of glycolysis in demyelinating disease in which heightened glycolysis promoted process extension as a measure of myelination and lowered aerobic glycolysis was shown to promote process retraction and oligodendrocyte survival that may be relevant to the human demyelinating disease multiple sclerosis (Rone et al., 2016). The later may relate to circumstance where IFN- γ has been shown to be beneficial to oligodendrocytes in experimental autoimmune encephalomyelitis, an important animal model for MS (Balabanov et al., 2007). The authors also showed that aerobic glycolysis was especially high in oligodendrocyte progenitors relative to mature oligodendrocytes indicating the importance of glycolysis in oligodendrocyte proliferation and myelin membrane formation. Thus, the study of glycolytic and mitochondrial metabolism is relevant for a better understanding of demyelinating diseases. Further, adequate oligodendrocyte glycolytic function is required to maintain axonal energy demands because lactate, a byproduct of glycolysis in oligodendrocytes, is necessary to support axonal mitochondrial

oxidative phosphorylation (Lee et al., 2012). Therefore, oligodendrocyte metabolic dysfunction may also contribute to axonal energy failure and eventually axonal degeneration. Understanding how SHP-1 regulates metabolic function in oligodendrocytes may further explain how these metabolic derangements occur.

1.6 Conclusions

Understanding how proinflammatory cytokines such as IFN- γ modulate metabolism is likely to be relevant to both autoimmune and virus-induced oligodendrocyte pathology and demyelinating diseases. Heretofore, IFN- γ was thought to induce oligodendrocyte pathology and demyelination by invoking a proinflammatory process that includes mobilization of myeloid cells against myelin and production of noxious molecules that damage oligodendrocytes (Corbin et al., 1996, Horwitz et al., 1997). It is plausible that IFN- γ may act directly on oligodendrocytes to alter bioenergetics in way not compatible with their role in both myelination and supportive functions for axons. Alternatively, many groups have reported that IFN- γ is protective in the context demyelinating processes such as EAE or virus-induced demyelination, which may be attributed to the ability of IFN- γ to downregulate oligodendrocyte metabolism in such a way as to maintain reduced virus replication and/or *promote* oligodendrocyte survival (Rone et al., 2016, Willenborg et al., 1996). Thus, the present observations suggest novel ways by which IFN- γ and SHP-1 may exert effects on CNS white matter by altering oligodendrocyte bioenergetics that affect either oligodendrocyte viability or pathology in a context-specific manner.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Daria LaRocca, Ross Gruber, and Anthony Paredes for their help with the isolation of oligodendrocytes. We also thank Wanda Coombs and Steven Taffet for their help with western immunoblotting and scientific discussion. This work was supported by R01NS073810 to PTM and F30NS095498 to SBM.

Abbreviations

2-DG	2-deoxyglucose
ECAR	extracellular acidification rate
ETC	electron transport chain
FCCP	carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazine
iNOS	inducible nitric oxide synthase
LIF	leukemia inhibitory factor
MCT	monocarboxylate transporter
me/me	motheaten

NO	nitric oxide
OCR	oxygen consumption rate
OXPHOS	oxidative phosphorylation
PV	pervanadate
R/AA	rotenone/antimycin A
SHP-1	src homology region 2 domain-containing phosphatase-1
WT	wild type

References

- Agresti C, Bernardo A, Del Russo N, Marziali G, Battistini A, Aloisi F, Coccia EM. 1998; Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNF-alpha in oligodendrocytes. *European Journal of Neuroscience*. 10:2975–2983. [PubMed: 9758167]
- Allonso D, Andrade IS, Conde JN, Coelho DR, Rocha DC, da Silva ML, Ventura GT, Silva EM, Mohana-Borges R. 2015; Dengue Virus NS1 Protein Modulates Cellular Energy Metabolism by Increasing Glyceraldehyde-3-Phosphate Dehydrogenase Activity. *J Virol*. 89:11871–11883. [PubMed: 26378175]
- Amaral AI, Meisinger TW, Kotter MR, Sonnewald U. 2013; Metabolic aspects of neuron-oligodendrocyte-astrocyte interactions. *Front Endocrinol (Lausanne)*. 4:1–5. [PubMed: 23355833]
- Andrews HE, Nichols PP, Bates D, Turnbull DM. 2005; Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis. *Med Hypotheses*. 64:669–677. [PubMed: 15694681]
- Avalle L, Pensa S, Regis G, Novelli F, Poli V. 2012; STAT1 and STAT3 in tumorigenesis: A matter of balance. *Jak-Stat*. 1:65–72. [PubMed: 24058752]
- Balabanov R, Strand K, Goswami R, McMahon E, Begolka W, Miller SD, Popko B. 2007; Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. *J Neurosci*. 27:2013–2024. [PubMed: 17314297]
- Balabanov R, Strand K, Kemper A, Lee JY, Popko B. 2006; Suppressor of cytokine signaling 1 expression protects oligodendrocytes from the deleterious effects of interferon-gamma. *J Neurosci*. 26:5143–5152. [PubMed: 16687505]
- Bergmann CC, Parra B, Hinton DR, Chandran R, Morrison M, Stohlman SA. 2003; Perforin-mediated effector function within the central nervous system requires IFN-gamma-mediated MHC up-regulation. *J Immunol*. 170:3204–3213. [PubMed: 12626579]
- Bjartmar C, Trapp BD. 2001; Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. *Current opinion in neurology*. 14:271–278. [PubMed: 11371748]
- Boehm U, Klamp T, Groot M, Howard JC. 1997; Cellular responses to interferon-gamma. *Annu Rev Immunol*. 15:749–795. [PubMed: 9143706]
- Buntinx M, Gielen E, Van Hummelen P, Raus J, Ameloot M, Steels P, Stinissen P. 2004; Cytokine-induced cell death in human oligodendroglial cell lines. II: Alterations in gene expression induced by interferon-gamma and tumor necrosis factor-alpha. *J Neurosci Res*. 76:846–861. [PubMed: 15160396]
- Cannella B, Raine CS. 2004; Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. *Ann Neurol*. 55:46–57. [PubMed: 14705111]
- Corbin JG, Kelly D, Rath EM, Baerwald KD, Suzuki K, Popko B. 1996; Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. *Mol Cell Neurosci*. 7:354–370. [PubMed: 8812062]
- David M, Chen HE, Goelz S, Larner AC, Neel BG. 1995; Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. *Mol Cell Biol*. 15:7050–7058. [PubMed: 8524272]

- De-Simone FI, Sariyer R, Otalora YL, Yarandi S, Craigie M, Gordon J, Sariyer IK. 2015; IFN-Gamma Inhibits JC Virus Replication in Glial Cells by Suppressing T-Antigen Expression. *PLoS ONE*. 10:e0129694. [PubMed: 26061652]
- Decker T, Kovarik P, Meinke A. 1997; GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. *J Interferon and Cytokine Res*. 17:121–134. [PubMed: 9085936]
- Findlay JS, Ulaeto D. 2015; Semliki Forest virus and Sindbis virus, but not vaccinia virus, require glycolysis for optimal replication. *J Gen Virol*. 96:2693–2696. [PubMed: 26297236]
- Fontaine KA, Sanchez EL, Camarda R, Lagunoff M. 2015; Dengue virus induces and requires glycolysis for optimal replication. *J Virol*. 89:2358–2366. [PubMed: 25505078]
- Funfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, Brinkmann BG, Kassmann CM, Tzvetanova ID, Mobius W, Diaz F, Meijer D, Suter U, Hamprecht B, Sereda MW, Moraes CT, Frahm J, Goebbels S, Nave KA. 2012; Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. *Nature*. 485:517–521. [PubMed: 22622581]
- Garcia-Perez C, Roy SS, Naghdi S, Lin X, Davies E, Hajnoczky G. 2012; Bid-induced mitochondrial membrane permeabilization waves propagated by local reactive oxygen species (ROS) signaling. *Proc Natl Acad Sci U S A*. 109:4497–4502. [PubMed: 22393005]
- Garedew A, Henderson SO, Moncada S. 2010; Activated macrophages utilize glycolytic ATP to maintain mitochondrial membrane potential and prevent apoptotic cell death. *Cell Death Differ*. 17:1540–1550. [PubMed: 20339378]
- Gonzalez JM, Bergmann CC, Fuss B, Hinton DR, Kangas C, Macklin WB, Stohlman SA. 2005; Expression of a dominant negative IFN-gammareceptor on mouse oligodendrocytes. *Glia*. 51:22–34. [PubMed: 15779088]
- Goverman J. 2009; Autoimmune T cell responses in the central nervous system. *Nat Rev Immunol*. 9:393–407. [PubMed: 19444307]
- Gruber RC, LaRocca D, Minchenberg SB, Christophi GP, Hudson CA, Ray AK, Shafit-Zagardo B, Massa PT. 2015; The control of reactive oxygen species production by SHP-1 in oligodendrocytes. *Glia*. 63:1753–1771. [PubMed: 25919645]
- Heales SJ, Bolanos JP, Stewart VC, Brookes PS, Land JM, Clark JB. 1999; Nitric oxide, mitochondria and neurological disease. *Biochim Biophys Acta*. 1410:215–228. [PubMed: 10076028]
- Hiroi M, Mori K, Sakaeda Y, Shimada J, Ohmori Y. 2009; STAT1 represses hypoxia-inducible factor-1-mediated transcription. *Biochem Biophys Res Commun*. 387:806–810. [PubMed: 19646959]
- Horvat A, Schwaiger FW, Hager G, Brocker F, Streif R, Knyazev PG, Ullrich A, Kreutzberg GW. 2001; A novel role for protein tyrosine phosphatase SHP1 in controlling glial activation in the normal and injured nervous system. *J Neurosci*. 21:865–874. [PubMed: 11157073]
- Horwitz MS, Evans CF, McGavern DB, Rodriguez M, Oldstone MBA. 1997; Primary demyelination in transgenic mice expressing interferon-gamma. *Nat Med*. 3:1037–1041. [PubMed: 9288735]
- Karhumaki E, Helin H. 1987; Regulation of oxidative metabolism by interferon-gamma during human monocyte to macrophage differentiation. *Med Biol*. 65:261–266. [PubMed: 2836672]
- Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, Liu Y, Tsingalia A, Jin L, Zhang PW, Pellerin L, Magistretti PJ, Rothstein JD. 2012; Oligodendroglia metabolically support axons and contribute to neurodegeneration. *Nature*. 487:443–448. [PubMed: 22801498]
- Lees JR, Cross AH. 2007; A little stress is good: IFN-gamma, demyelination, and multiple sclerosis. *J Clin Invest*. 117:297–299. [PubMed: 17273549]
- Lin W, Bailey SL, Ho H, Harding HP, Ron D, Miller SD, Popko B. 2007; The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. *J Clin Invest*. 117:448–456. [PubMed: 17273557]
- Lin W, Kemper A, Dupree JL, Harding HP, Ron D, Popko B. 2006; Interferon-gamma inhibits central nervous system remyelination through a process modulated by endoplasmic reticulum stress. *Brain*. 129:1306–1318. [PubMed: 16504972]
- Liu B, Fang M, He Z, Cui D, Jia S, Lin X, Xu X, Zhou T, Liu W. 2015; Hepatitis B virus stimulates G6PD expression through HBx-mediated Nrf2 activation. *Cell death & disease*. 6:e1980. [PubMed: 26583321]

- Loda E, Balabanov R. 2012; Interferon regulatory factor 1 regulation of oligodendrocyte injury and inflammatory demyelination. *Reviews in the neurosciences*. 23:145–152. [PubMed: 22499673]
- Ma T, Patel H, Babapoor-Farrokhran S, Franklin R, Semenza GL, Sodhi A, Montaner S. 2015 KSHV induces aerobic glycolysis and angiogenesis through HIF-1-dependent upregulation of pyruvate kinase 2 in Kaposi's sarcoma. *Angiogenesis*.
- Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, Lassmann H, Turnbull DM. 2009; Mitochondrial changes within axons in multiple sclerosis. *Brain*. 132:1161–1174. [PubMed: 19293237]
- Massa PT, Saha S, Wu C, Jarosinski KW. 2000; Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes. *Glia*. 29:376–385. [PubMed: 10652447]
- Massa PT, Wu C. 1996; The role of protein tyrosine phosphatase SHP-1 in the regulation of IFN- γ signaling in neural cells. *J Immunol*. 157:5139–5144. [PubMed: 8943425]
- Massa PT, Wu C, Fecenko-Tacka K. 2004; Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice. *J Neurosci Res*. 77:15–25. [PubMed: 15197735]
- Meier JA, Larner AC. 2014 Toward a new STATE: The role of STATs in mitochondrial function. *Semin Immunol*.
- Parra GI, Bergmann CC, Phares TW, Hinton DR, Atkinson R, Stohlman SA. 2010; Gamma interferon signaling in oligodendrocytes is critical for protection from neurotropic coronavirus infection. *J Virol*. 84:3111–3115. [PubMed: 20042510]
- Pitroda SP, Wakim BT, Sood RF, Beveridge MG, Beckett MA, MacDermid DM, Weichselbaum RR, Khodarev NN. 2009; STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. *BMC medicine*. 7:68. [PubMed: 19891767]
- Poli V, Camporeale A. 2015; STAT3-Mediated Metabolic Reprogramming in Cellular Transformation and Implications for Drug Resistance. *Frontiers in oncology*. 5:121. [PubMed: 26106584]
- Ramana CV, Grammatikakis N, Chernov M, Nguyen H, Goh KC, Williams BRG. 2000; Regulation of c-myc expression by IFN- γ through Stat1-dependent and -independent pathways. *EMBO Journal*. 19:263–272. [PubMed: 10637230]
- Renno T, Taupin V, Bourbonniere L, Verge G, Tran E, De Simone R, Krakowski M, Rodriguez M, Peterson A, Owens T. 1998; Interferon- γ in progression to chronic demyelination and neurological deficit following acute EAE. *Mol Cell Neurosci*. 12:376–389. [PubMed: 9888990]
- Rinholt JE, Hamilton NB, Kessaris N, Richardson WD, Bergersen LH, Attwell D. 2011; Regulation of oligodendrocyte development and myelination by glucose and lactate. *J Neurosci*. 31:538–548. [PubMed: 21228163]
- Rone MB, Cui QL, Fang J, Wang LC, Zhang J, Khan D, Bedard M, Almazan G, Ludwin SK, Jones R, Kennedy TE, Antel JP. 2016; Oligodendroglialopathy in Multiple Sclerosis: Low Glycolytic Metabolic Rate Promotes Oligodendrocyte Survival. *J Neurosci*. 36:4698–4707. [PubMed: 27122029]
- Saab AS, Tzvetanova ID, Nave KA. 2013; The role of myelin and oligodendrocytes in axonal energy metabolism. *Curr Opin Neurobiol*. 23:1065–1072. [PubMed: 24094633]
- Sanchez EL, Lagunoff M. 2015 Viral activation of cellular metabolism. *Virology*. :479–480. 609–618.
- Sarafian TA, Montes C, Imura T, Qi J, Coppola G, Geschwind DH, Sofroniew MV. 2010; Disruption of Astrocyte STAT3 Signaling Decreases Mitochondrial Function and Increases Oxidative Stress In Vitro. *PLoS ONE*. 5:e9532. [PubMed: 20224768]
- Schijns VE, Van der Neut R, Haagmans BL, Bar DR, Schellekens H, Horzinek MC. 1991; Tumour necrosis factor- α , interferon- γ and interferon- β exert antiviral activity in nervous tissue cells. *J Gen Virol*. 72(Pt 4):809–815. [PubMed: 1849968]
- Shuai K, Liu B. 2003; Regulation of JAK-STAT signalling in the immune system. *Nat Rev Immunol*. 3:900–911. [PubMed: 14668806]
- Sisler JD, Morgan M, Raje V, Grande RC, Derecka M, Meier J, Cantwell M, Szczepanek K, Korzun WJ, Lesniewski EJ, Harris TE, Croniger CM, Larner AC. 2015; The Signal Transducer and Activator of Transcription 1 (STAT1) Inhibits Mitochondrial Biogenesis in Liver and Fatty Acid Oxidation in Adipocytes. *PLoS ONE*. 10:e0144444. [PubMed: 26689548]

- Sosa RA, Murphey C, Robinson RR, Forsthuber TG. 2015; IFN-gamma ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation. *Proc Natl Acad Sci U S A*. 112:E5038–5047. [PubMed: 26305941]
- Starr R, Hilton DJ. 1999; Negative regulation of the JAK/STAT pathway. *Bioessays*. 21:47–52. [PubMed: 10070253]
- Steiner J, Martins-de-Souza D, Schiltz K, Sarnyai Z, Westphal S, Isermann B, Dobrowolny H, Turck CW, Bogerts B, Bernstein HG, Horvath TL, Schild L, Keilhoff G. 2014; Clozapine promotes glycolysis and myelin lipid synthesis in cultured oligodendrocytes. *Frontiers in cellular neuroscience*. 8:384. [PubMed: 25477781]
- Su X, Yu Y, Zhong Y, Giannopoulou EG, Hu X, Liu H, Cross JR, Ratsch G, Rice CM, Ivashkiv LB. 2015; Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation. *Nat Immunol*. 16:838–849. [PubMed: 26147685]
- Sykes JE, Lopes-Cardozo M, Van Den Bergh SG. 1986; Relationship between the pentose-phosphate pathway and the de novo synthesis of fatty acids and cholesterol in oligodendrocyte-enriched glial cultures. *Neurochem Int*. 8:77–82. [PubMed: 20493032]
- Szczepanek K, Lesnefsky EJ, Larner AC. 2012; Multi-tasking: nuclear transcription factors with novel roles in the mitochondria. *Trends Cell Biol*.
- Takikita S, Takano T, Narita T, Maruo Y. 2015; Increased apoptosis and hypomyelination in cerebral white matter of macular mutant mouse brain. *Mol Genet Metab Rep*. 4:25–29. [PubMed: 26937406]
- Tirotta E, Ransohoff RM, Lane TE. 2011; CXCR2 signaling protects oligodendrocyte progenitor cells from IFN-gamma/CXCL10-mediated apoptosis. *Glia*. 59:1518–1528. [PubMed: 21656856]
- Tran EH, Prince EN, Owens T. 2000; IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. *J Immunol*. 164:2759–2768. [PubMed: 10679118]
- Tsunoda I, Libbey JE, Kobayashi-Warren M, Fujinami RS. 2006; IFN-gamma production and astrocyte recognition by autoreactive T cells induced by Theiler's virus infection: role of viral strains and capsid proteins. *J Neuroimmunol*. 172:85–93. [PubMed: 16375978]
- Valentino L, Pierre J. 2006; JAK/STAT signal transduction: regulators and implication in hematological malignancies. *Biochem Pharmacol*. 71:713–721. [PubMed: 16426581]
- Vartanian T, Li Y, Zhao M, Stefansson K. 1995; Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. *Mol Med*. 1:732–743. [PubMed: 8612196]
- Watanabe Y, Suzuki O, Haruyama T, Akaike T. 2003; Interferon-gamma induces reactive oxygen species and endoplasmic reticulum stress at the hepatic apoptosis. *J Cell Biochem*. 89:244–253. [PubMed: 12704788]
- Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, Moh A, Moghaddas S, Chen Q, Bobbili S, Cichy J, Dulak J, Baker DP, Wolfman A, Stuehr D, Hassan MO, Fu XY, Avadhani N, Drake JJ, Fawcett P, Lesnefsky EJ, Larner AC. 2009; Function of mitochondrial Stat3 in cellular respiration. *Science*. 323:793–797. [PubMed: 19131594]
- Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. 1996; IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. *J Immunol*. 157:3223–3227. [PubMed: 8871615]
- Wishcamper CA, Coffin JD, Lurie DI. 2001; Lack of the protein tyrosine phosphatase SHP-1 results in decreased numbers of glia within the motheten (me/me) mouse brain. *J Comp Neurol*. 441:118–133. [PubMed: 11745639]
- Wong LH, Sim H, Chatterjee-Kishore M, Hatzinisiriou I, Devenish RJ, Stark G, Ralph SJ. 2002; Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1. *J Biol Chem*. 277:19408–19417. [PubMed: 11909852]
- Ziabreva I, Campbell G, Rist J, Zamboni J, Rorbach J, Wydro MM, Lassmann H, Franklin RJ, Mahad D. 2010; Injury and differentiation following inhibition of mitochondrial respiratory chain complex IV in rat oligodendrocytes. *Glia*. 58:1827–1837. [PubMed: 20665559]

Highlights

- IFN- γ decreases aerobic glycolysis in oligodendrocytes
- IFN- γ induces STAT1 activation in oligodendrocytes
- Induction of STAT1 by IFN- γ is negatively regulated by SHP-1
- Mitochondrial respiration in oligodendrocytes is significantly affected by IFN- γ
- Pathological and beneficial biological activities of IFN- γ on oligodendrocytes may rely on effects on bioenergetics

Figure 1.

Constitutive and *in vivo* IFN- γ treated wild type mouse oligodendrocyte metabolism. A) Seahorse extracellular flux analyzer graph depicting the change in extracellular acidification (ECAR) over time for oligodendrocytes isolated from untreated wild type (WT) mice, and from mice injected IP with IFN- γ for 24 hours (WT n=5, WT IFN- γ n=7). B&C) Scatter plot graphs depicting B) basal glycolysis (p=0.0013; WT n=5, WT IFN- γ n=7) and C) glycolytic capacity (p=0.0005; WT n=5, WT IFN- γ n=7) of oligodendrocytes from untreated WT mice and WT mice treated with IFN- γ . D) Seahorse extracellular flux analyzer graph depicting the oxygen consumption rate (OCR) over time for oligodendrocytes isolated from untreated WT mice and WT mice treated with IFN- γ (WT n=5, WT IFN- γ n=7). E–H) Scatter plot graphs depicting E) basal mitochondrial oxygen consumption (p=0.0005; WT n=5, WT IFN- γ n=7), F) maximal mitochondrial respiration (p=0.0012; WT n=5, WT IFN- γ n=7), G) ATP production (p=0.0044; WT n=5, WT IFN- γ n=7), and H) spare respiratory capacity (p=0.0114; WT n=5, WT IFN- γ n=7) of oligodendrocytes isolated from untreated and IFN- γ treated mice. Graphs depict

oligodendrocytes isolated from the brains and spinal cords of P6–P8 mice, standardized to GAPDH levels to control for cell numbers between samples. Each data point represents oligodendrocytes derived from a single mouse and significance was determined by unpaired one-tailed Student's t-test (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). *Glycolytic capacity is the maximal rate the cell can perform glycolysis and is closely related to the expression level of glycolytic enzymes in the cell. This differs from basal glycolysis which is influenced by other factors, mainly mitochondrial ATP production. Maximal mitochondrial respiration is the maximal rate the mitochondria can consume oxygen and is related to the expression and posttranslational modification of complexes in the ETC in the oligodendrocytes. This differs from basal mitochondrial oxygen consumption which is regulated by various factors, mainly glycolytic ATP production. A description of different Seahorse measurements and conditions under which measurements are made is shown in supplementary figure 1.*

Figure 2.

Glycolytic and mitochondrial metabolism of wild type oligodendrocytes treated *in vitro* with IFN- γ . A) Seahorse extracellular flux analyzer graph depicting the change in extracellular acidification (ECAR) over time for oligodendrocytes isolated from wild type (WT) mice and treated *in vitro* with PBS (control) or 100 U/ml IFN- γ for 24 hours (WT n=8, WT IFN- γ n=9). B&C) Scatter plot graphs depicting B) basal glycolysis (p=0.0016; WT n=8, WT IFN- γ n=9) and C) glycolytic capacity (p=0.0360; WT n=8, WT IFN- γ n=9) of oligodendrocytes from WT mice treated *in vitro* with PBS or IFN- γ . D) Seahorse extracellular flux analyzer graph depicting the oxygen consumption rate (OCR) over time for oligodendrocytes isolated from WT mice treated *in vitro* with either PBS (control) or IFN- γ for 24 hours (WT n=4, WT IFN- γ n=4). E–H) Scatter plot graphs depicting E) basal mitochondrial oxygen consumption (p=0.0268; WT n=5, WT IFN- γ n=5), F) maximal mitochondrial respiration (p=0.1650; WT n=4, WT IFN- γ n=5), G) ATP production (p=0.2075; WT n=5, WT IFN- γ n=5), and H) spare respiratory capacity (p=0.3299; WT n=4, WT IFN- γ n=4) of oligodendrocytes isolated from WT mice treated *in vitro* with PBS or WT IFN- γ . Graphs depict oligodendrocytes isolated from the brains and spinal cords of P7 mice, standardized

to CyQUANT to control for cell number between samples. Each data point represents individual replicates of oligodendrocytes pooled together from multiple WT mice and significance was determined by unpaired one-tailed Student's t-test (* $p < 0.05$, ** $p < 0.01$).

Figure 3.

Constitutive and IFN- γ -inducible STAT1 and Y705-pSTAT3 expression in wild type oligodendrocytes. A) Bar graphs and representative western blots showing Y701-pSTAT1 band density relative to actin ($p=0.0064$; WT $n=3$, WT IFN- γ $n=3$) and total STAT1 relative to GAPDH in oligodendrocytes isolated from untreated wild type (WT) and IFN- γ treated WT mice ($p=0.0043$; WT $n=3$, WT IFN- γ $n=3$). The lysates analyzed for Y701-pSTAT1 were perfused with 100mM pervanadate (PV) to preserve phosphorylated STAT1, which is highly labile in fresh tissues. B) Bar graph and representative western blot depicting Y705-

pSTAT3 band density relative to GAPDH in oligodendrocytes isolated from untreated WT and IFN- γ treated WT mice ($p=0.1693$; WT $n=9$, WT IFN- γ $n=3$). C) Bar graphs and representative western blot showing Y701-pSTAT1 band density relative to actin ($p=0.0001$; WT $n=3$, WT IFN- γ $n=3$) and total STAT1 relative to actin in oligodendrocytes isolated from WT mice and treated *in vitro* with IFN- γ ($p=0.0016$; WT $n=3$, WT IFN- γ $n=3$). D) Bar graph and representative western blot depicting Y705-pSTAT3 band density relative to actin in oligodendrocytes isolated from WT mice and treated *in vitro* with IFN- γ ($p=0.4870$; WT $n=3$, WT IFN- γ $n=3$). Each data point represents oligodendrocytes derived from separate mice. Statistical significance was determined by unpaired one-tailed Student's t-test (** $p<0.01$, *** $p<0.001$).

Figure 4.

Constitutive and IFN- γ -inducible STAT1 and Y705-pSTAT3 expression in wild type and SHP-1-deficient oligodendrocytes. A) Bar graphs and representative western blot showing STAT1 α and STAT1 β band density relative to actin in wild type (WT) and oligodendrocytes from SHP-1 deficient (motheaten, me/me) mice (STAT1 α : p=0.0306; WT n=4, me/me n=4; STAT1 β : p=0.0309; WT n=4, me/me n=4). B) Bar graph and representative western blot depicting Y705-pSTAT3 band density relative to actin in oligodendrocytes isolated from WT and me/me mice (p=0.1157; WT n=4, me/me n=3). C&D) Bar graphs and E) representative

western blots showing inducible C) Y701-pSTAT1 and D) total STAT1 relative to actin in WT and me/me oligodendrocytes treated *in vitro* with either IFN- γ or leukemia inhibitory factor (LIF) relative to untreated oligodendrocytes. Statistical significance was determined by Student's t-test or a one-way ANOVA with Tukey's multiple comparisons test (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$).

Figure 5.

Constitutive wild type and SHP-1-deficient mouse oligodendrocyte metabolism. A) Seahorse extracellular flux analyzer graph depicting the change in extracellular acidification (ECAR) over time for oligodendrocytes isolated from wild type (WT) and SHP-1 deficient (motheaten, me/me) mice (WT n=5, me/me n=5). B&C) Scatter plot graphs depicting B) basal glycolysis (p=0.0063; WT n=5, me/me n=5) and C) glycolytic capacity (p=0.0284; WT n=5, me/me n=5) from freshly isolated oligodendrocytes isolated from WT and me/me mice. D) Seahorse extracellular flux analyzer graph depicting the oxygen consumption rate (OCR) over time for oligodendrocytes isolated from untreated WT mice and me/me mice (WT n=4, me/me n=5). E–H) Scatter plot graphs depicting E) basal mitochondrial oxygen consumption (p=0.0077; WT n=5, me/me n=6), F) maximal mitochondrial respiration (p=0.0043; WT n=5, WT IFN- γ n=6), G) ATP production (p=0.0071; WT n=5, WT IFN- γ n=6), and H) spare respiratory capacity (p=0.0051; WT n=5, WT IFN- γ n=6) of oligodendrocytes isolated from WT and me/me mice. Data points are representative of oligodendrocytes isolated from five separate P6–P8 mice and were standardized to GAPDH

levels to control for cell numbers between samples. Statistical significance was determined by unpaired one-tailed Student's t-test (* $p < 0.05$, ** $p < 0.01$).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 6.

Total STAT1 and Y705-pSTAT3 expression in oligodendrocytes from SHP-1-deficient mice treated *in vivo* with IFN- γ . A) Bar graph and representative western blot showing total STAT1 band density relative to GAPDH in oligodendrocytes isolated from untreated and IFN- γ treated SHP-1-deficient (motheaten, me/me) mice ($p=0.0284$; me/me $n=4$, me/me IFN- γ $n=4$). B) Bar graph and representative western blot depicting Y705-pSTAT3 relative to GAPDH in oligodendrocytes isolated from untreated me/me mice and IFN- γ -treated me/me mice ($p=0.4489$; me/me $n=5$, me/me IFN- γ $n=3$). Data points depict oligodendrocytes isolated from the brains and spinal cords of individual animals. Statistical significance was determined by unpaired one-tailed Student's t-test ($*p<0.05$).

Figure 7.

Constitutive and *in vivo* IFN- γ -treated SHP-1-deficient oligodendrocyte metabolism. A) Seahorse extracellular flux analyzer graph depicting the change in extracellular acidification (ECAR) over time for oligodendrocytes isolated from untreated SHP-1-deficient (motheaten, me/me) mice and IFN- γ me/me mice (me/me n=4, me/me IFN- γ n=4). B&C) Scatter plot graphs depicting B) basal glycolysis (p=0.2572; me/me n=3, me/me IFN- γ n=4) and C) glycolytic capacity (p=0.3780; me/me n=3, me/me IFN- γ n=4) of oligodendrocytes from untreated me/me mice and me/me mice treated with IFN- γ . D) Seahorse extracellular flux analyzer graph depicting the oxygen consumption rate (OCR) over time for oligodendrocytes isolated from untreated me/me mice, and me/me mice treated with IFN- γ (me/me n=4, me/me IFN- γ n=4). E–H) Scatter plot graphs depicting E) basal mitochondrial oxygen consumption (p=0.4188; me/me n=4, me/me IFN- γ n=4), F) maximal mitochondrial respiration (p=0.3649; me/me n=4, me/me IFN- γ n=4), G) ATP production (p=0.2879; me/me n=4, me/me IFN- γ n=4), and H) spare respiratory capacity (p=0.2563; me/me n=4, me/me IFN- γ n=4) of oligodendrocytes isolated from untreated and IFN- γ treated me/me

mice. Graphs depict oligodendrocytes isolated from the brains and spinal cords of P7–P8 mice, standardized to GAPDH levels to control for cell numbers between samples. Each data point represents oligodendrocytes derived from a single mouse and significance was determined by unpaired one-tailed Student's t-test.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 8.

Schematic diagram of potential pathways by which IFN- γ and SHP-1 regulate oligodendrocyte glycolytic and mitochondrial metabolism. *In vivo* action of IFN- γ or SHP-1 deficiency in oligodendrocytes leads to heightened STAT1 activity that correlates with reduced glycolysis. Reduced glycolysis would reduce the amount of lactate produced, however, mitochondrial metabolism is also reduced in oligodendrocytes thus sparing lactate for use in axonal mitochondria metabolism via transfer through monocarboxylate transporters (MCT) MCT1 and MCT2 channels located on the myelin membrane and axonal membrane respectively (Funfschilling et al., 2012, Rinholm et al., 2011). Direct signaling of IFN- γ on oligodendrocytes *in vitro* resulted in reduced glycolysis, however we propose that mitochondrial metabolism is reduced by other pathways stimulated by IFN- γ *in vivo*. One likely indirect effect of IFN- γ on oligodendrocytes only seen *in vivo* is the induction of inducible nitric oxide synthase (iNOS) by astrocytes which then secrete NO in the vicinity of oligodendrocytes (Tran et al., 2000). NO is known to downregulate mitochondrial respiration (Heales et al., 1999) which may preserve lactate levels to mitigate direct effects of IFN- γ on glycolysis in oligodendrocytes and preserve axonal function during inflammatory disease.